News articles about RedHill Biopharma (NASDAQ:RDHL) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. RedHill Biopharma earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.5826053797459 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of equities research analysts have recently issued reports on the stock. Seaport Global Securities assumed coverage on shares of RedHill Biopharma in a research note on Friday, October 6th. They issued a “buy” rating and a $19.00 price objective for the company. Roth Capital reaffirmed a “buy” rating and issued a $27.00 price objective on shares of RedHill Biopharma in a research note on Wednesday, October 4th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target (up from $33.00) on shares of RedHill Biopharma in a report on Wednesday, October 4th. Finally, Zacks Investment Research upgraded shares of RedHill Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, September 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. RedHill Biopharma has an average rating of “Buy” and a consensus price target of $21.10.
RedHill Biopharma (NASDAQ:RDHL) opened at $5.17 on Friday. The stock has a market cap of $110.62, a PE ratio of -1.91 and a beta of 1.01. RedHill Biopharma has a 12 month low of $4.30 and a 12 month high of $11.25.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect RedHill Biopharma (RDHL) Share Price” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/14/redhill-biopharma-rdhl-receiving-somewhat-favorable-press-coverage-study-finds.html.
About RedHill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.